Crossmark

Targeting RNA with small molecules using state-of-the-art methods provides highly predictive affinities of riboswitch inhibitors

Published Online: 2025-10-01

Authors

Ansari, Narjes https://orcid.org/0000-0003-2017-8431
Liu, Chengwen

Hédin, Florent https://orcid.org/0000-0001-6341-7557
Hénin, Jérôme https://orcid.org/0000-0003-2540-4098
Ponder, Jay W. https://orcid.org/0000-0001-5450-9230
Ren, Pengyu

Piquemal, Jean-Philip https://orcid.org/0000-0001-6615-9426
Lagardère, Louis https://orcid.org/0000-0002-7251-0910
El Hage, Krystel https://orcid.org/0000-0003-4837-3888
Funding

Funding for this research was provided by:

Grand Equipement de Calcul Intensif (GENCI), Institut du Développement et des Ressources en Informatique(IDRIS), Centre Informatique de l’Enseignement Supérieur
License Information

Text and Data Mining valid from 2025-10-01

Version of Record valid from 2025-10-01
More Information

Article History

Received: 8 November 2024

Accepted: 28 August 2025

First Online: 1 October 2025

Competing interests

: J.W.P., P.R., J-P.P., and L.L. are co-founders and shareholders of Qubit Pharmaceuticals. All other authors declare no competing interests.

Document is current